Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 971-978

  Lund, Eva L ^a   Bastholm, Lone ^a   Kristjansen, Paul E G ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; COMBINED MODALITY THERAPY; CYCLOHEXANES; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; LYMPHOKINES; MALE; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEINS; RNA, MESSENGER; SESQUITERPENES; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034099423     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
2. Lund, E. L., Spang-Thomsen, M., Skovgaard-Poulsen, H., and Kristjansen, P. E. G. Tumor angiogenesis - a new therapeutic target in gliomas. Acta Neurol. Scand., 97: 52-62, 1998.
3. Cheng, S. Y., Huang, H. J., Nagane, M., Ji, X. D., Wang, D., Shih, C. C., Arap, W., Huang, C. M., and Cavenee, W. K. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA, 93: 8502-8507, 1996.
4. Castronovo, V., and Belotti, D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur. J. Cancer, 32A: 2520-2527, 1996.
5. Griffith, E. C., Su, Z., Turk, B. E., Chen, S., Chang, Y. H., Wu, Z., Biemann, K., and Liu, J. O. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol., 4: 461-471, 1997.
6. Yoshida, T., Kaneko, Y., Tsukamoto, A., Han, K., Ichinose, M., and Kimura, S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res., 58: 3751-3756, 1998.
7. Bernsen, H. J., Rijken, P. F., Peters, H., Bakker, H., and van-der-Kogel, A. J. The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J. Neurooncol., 38: 51-57, 1998.
8. Taki, T., Ohnishi, T., Arita, N., Hiraga, S., Saitoh, Y., Izumoto, S., Mori, K., and Hayakawa, T. Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis. J. Neurooncol., 19: 251-258, 1994.
9. Isobe, N., Uozumi, T., Kurisu, K., and Kawamoto, K. Experimental studies of the antitumor effect of TNP-470 on malignant brain tumors. Antitumor effect of TNP-470 on a human medulloblastoma xenograft line. Neuropediatrics, 27: 136-142, 1996.
10. Wassberg, E., Pahlman, S., Westlin, J. E., and Christofferson, R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr. Res., 41: 327-333, 1997.
11. Kragh, M., Spang-Thomsen, M., and Kristjansen, P. E. G. Time until initiation of tumor growth is an effective measure of the antiangiogenic effect of TNP-470 on human glioblastoma in nude mice. Oncol. Rep., 6: 759-762, 1999.
12. Murata, R., Nishimura, Y., and Hiraoka, M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 37: 1107-1113, 1997.
13. Teicher, B. A., Holden, S. A., Ara, G., Korbut, T., and Menon, K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother. Pharmacol., 38: 169-177, 1996.
14. Teicher, B. A., Holden, S. A., Dupuis, N. P., Kakeji, Y., Ikebe, M., Emi, Y., and Goff, D. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat., 36: 227-236, 1995.
15. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394: 287-291, 1998.
16. Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., and Wiegand, S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (Washington DC), 284: 1994-1998, 1999.
17. Yuan, F., Salehi, H. A., Boucher, Y., Vasthare, U. S., Tuma, R. F., and Jain, R. K. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res., 54: 4564-4568, 1994.
18. Takamiya, Y., Brem, H., Ojeifo, J., Mineta, T., and Martuza, R. L. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery, 34: 869-875, 1994.
19. Wilson, J. T., and Penar, P. L. The effect of AGM-1470 in an improved intracranial 9L gliosarcoma rat model. Neurol. Res., 16: 121-124, 1994.
20. Krishnan, L., Krishnan, E. C., and Jewell, W. R. Immediate effect of irradiation on microvasculature. Int. J. Radiat. Oncol. Biol. Phys., 15: 147-150, 1988.
21. Kohn, S., Fradis, M., Podoshin, L., Ben David, J., Zidan, J., and Robinson, E. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct. Pathol., 21: 289-299, 1997.
22. Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, S. D., Davis, S., Sato, T. N., and Yancopoulos, G. D. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87: 1171-1180, 1996.
23. Siemeister, G., Schirner, M., Weindel, K., Reusch, P., Menrad, A., Manne, D., and Martiny-Baron, G. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res., 59: 3185-3191, 1999.
24. Roberts, W. G., and Palade, G. E. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res., 57: 765-772, 1997.
25. Teicher, B. A., Holden, S. A., Ara, G., Dupuis, N. P., Liu, F., Yuan, J., Ikebe, M., and Kakeji, Y. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int. J. Cancer, 61: 732-737, 1995.
26. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
27. Shweiki, D., Neeman, M., Itin, A., and Keshet. E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis Proc. Natl. Acad. Sci. USA, 92: 768-772, 1995.
28. White, F. C., Carroll, S. M., and Kamps, M. P. VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors, 12: 289-301, 1995.